France Next Generation Sequencing Market

The France next-generation sequencing market is projected to grow from USD 0.59 billion in 2026 to USD 1.14 billion by 2031, at a CAGR of 14.2% during the forecast period. This market is expanding rapidly due to substantial government investments in genomics research, the launch of national genomic medicine initiatives, the increasing adoption of precision medicine approaches, and the growing demand for advanced diagnostic and therapeutic applications across healthcare sectors.

The France next-generation sequencing market is characterized by major global players, including Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and QIAGEN (Netherlands). These leading players maintain competitive positions by advancing sequencing platform technologies, expanding sequencing and bioinformatics service capabilities, developing innovative consumables and reagents, forming strategic partnerships with research institutions and healthcare providers, and delivering faster, more accurate, cost-efficient sequencing solutions across diagnostics, drug discovery, and research applications.

To know about the assumptions considered for the study download the pdf brochure

Illumina, Inc. (US) is a leading provider of next-generation sequencing platforms and consumables serving research, clinical, and applied markets globally, with a significant presence in France. The company's comprehensive portfolio spans high-throughput sequencing systems, targeted panels, library preparation kits, and integrated bioinformatics solutions that enable genomic analysis across oncology, reproductive health, genetic disease, and infectious disease applications. Illumina has established itself as a trusted partner for genomic research institutions, clinical laboratories, and pharmaceutical companies requiring scalable, accurate sequencing technologies.

Thermo Fisher Scientific, Inc. (US) is a technology-driven life science company specializing in sequencing platforms, consumables, and integrated workflow solutions for genomics research and clinical applications across France and Europe. Combining instrument development, reagent manufacturing, and bioinformatics software into comprehensive sequencing workflows, Thermo Fisher significantly enhances laboratory productivity, data quality, and turnaround times compared to fragmented approaches. The company’s Ion Torrent sequencing systems and supporting consumables enable applications ranging from targeted gene panels to whole-genome sequencing, offering laboratories flexibility, scalability, and cost-effectiveness.

MARKET RANKING

Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), and Agilent Technologies, Inc. (US) are the leading companies in the France next-generation sequencing market. Illumina is recognized for its comprehensive high-throughput and benchtop sequencing platforms serving research and clinical laboratories, supported by extensive consumables portfolios and bioinformatics tools. Thermo Fisher Scientific specializes in Ion Torrent semiconductor sequencing technology, integrating scalable platforms, targeted sequencing panels, and workflow automation for diverse genomic applications. Agilent Technologies is known for its target enrichment solutions, library preparation systems, and quality control products that enable precise, efficient sample preparation for next-generation sequencing workflows across multiple application areas.

Related Reports:

France Next-generation Sequencing Market by Product (Reagents, Kits, Platforms), Service (CHIP Sequencing, Whole Genome, Methyl, RNA Sequencing), Technology (SBS, Nanopore) Workflow (Sequencing, Data Analysis), Application, Competition - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com